Entries |
Document | Title | Date |
20080214663 | Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use - Levodopa dimethyl-substituted diester prodrugs pharmaceutical, compositions comprising levodopa dimethyl-substituted diester prodrugs, and methods of using such prodrugs and pharmaceutical compositions for treating diseases such as Parkinson's disease are provided. | 09-04-2008 |
20080312322 | Organic Compounds - A compound of formula (I); in free or pharmaceutically acceptable salt form, where R | 12-18-2008 |
20090005446 | Prophylactic Antistress Agent - The present invention relates to a prophylactic antistress agent and a central fatigue improver, which contain chlorogenic acids or pharmaceutically acceptable salts thereof as active ingredients. The present invention makes it possible to prevent and improve mental task fatigue, physical fatigue, central fatigue, central fatigue syndrome, overwork and the like. | 01-01-2009 |
20090012160 | Carnitine Conjugates As Dual Prodrugs, Methods Of Production And Uses Thereof - The present invention discloses novel dual prodrug compounds of formula (1), methods for their preparation and intermediates in their syntheses, formula (1): wherein A is a single bond, —O—, or —CH | 01-08-2009 |
20090036525 | Non-Natural Amino Acid Derivatives - Compounds of formula (I) have activity in alleviating the effects of impaired dopaminergic signaling, for example in the treatment of Parkinsons Disease: | 02-05-2009 |
20090042980 | Neuroprotective compositions and methods - Neurite outgrowth-promoting prostaglandins (NEPPs) and other electrophilic compounds bind to Keap1, a negative regulator of the transcription factor Nrf2, and prevent Keap1-mediated inactivation of Nrf2 and, thus, enhance Nrf2 translocation into the nucleus of neuronal cells. Therefore, neuroprotective compositions and related methods are provided that employ such neuroprotective compounds, and prodrugs of such compounds, to cause dissociation of Nrf2 from a Keap1/Nrf2 complex. | 02-12-2009 |
20090042981 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES - The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions. | 02-12-2009 |
20090076143 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND INFLAMMATION-RELATED DISORDERS BY PLECTRANTHUS AMBOINICUS EXTRACTS - The crude extract of | 03-19-2009 |
20090124689 | CETP Inhibitors - Compounds having a biphenyl group substituted with a phenyl or heteroaromatic group, as shown in Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: | 05-14-2009 |
20090137668 | C-NITROSO-DERIVED NITROXYL DONORS - Active compounds of Formula (I) are described: wherein: R | 05-28-2009 |
20090156670 | NONAQUEOUS LIQUID PARENTERAL ACECLOFENAC FORMULATION - A nonaqueous liquid parenterally deliverable pharmaceutical formulation, and more particularly a nonaqueous liquid parenteral Aceclofenac formulation comprising the selective NSAID Aceclofenac, is disclosed. A process of preparing Aceclofenac formulation, the therapeutic dosage form and storage of dose, and the method of treating a subject having a condition or a disorder wherein treatment with NSAID is indicated, are also disclosed. Diclofenac formed by conversion of Aceclofenac is solubilized by the nonaqueous solubilizer(s), which are substantially inert with respect to such conversion. The composition has Aceclofenac salt stabilizing means for inhibiting precipitation of Aceclofenac. The compositions disclosed in the present invention are stable upon storage at room temperature and at refrigerated temperatures. Compositions disclosed in the present invention, whether ready-to-use or requiring dilution prior to administration, can be prepared by inexpensive processes disclosed herein. | 06-18-2009 |
20090170937 | Amino Acid Derivatives - Compounds of formula (I) have activity in alleviating the effects of impaired dopaminergic signaling, for example in the treatment of Parkinsons Disease: | 07-02-2009 |
20090192221 | CARBAMATE ANTIBIOTICS - The invention relates to the field of antibiotic compositions, both inside and outside the medical field. Presented is a new class of antibiotic compounds around the lead compound (3,4-dichloro-phenyl)-carbamic acid 2-isobutoxycarbonylamino-1-methyl-ethyl ester, which are especially useful for combating infections with gram-positive bacteria and especially MRSA. | 07-30-2009 |
20090192222 | MESOPHASIC FORMS OF (3S)-AMINOMETHYL-5-METHYL-HEXANOIC ACID PRODRUGS AND METHODS OF USE - Mesophasic forms of (3S)-aminomethyl-5-hexanoic acid prodrugs and methods of preparing and methods of using mesophasic forms of (3S)-aminomethyl-5-hexanoic acid prodrugs are provided. | 07-30-2009 |
20090203777 | ORGANIC COMPOUNDS - The invention describes novel pharmaceutically acceptable salt forms of camostat, processes for lyophilisation, taste-masked formulations, nebulised formulations and the use of each of the fore-going in the treatment of respiratory diseases, particularly cystic fibrosis and chronic obstructive pulmonary disease (COPD). | 08-13-2009 |
20090264524 | AGENT FOR RECOVERY FROM CEREBRAL FATIGUE - The present invention relates to a recuperative agent for cerebral fatigue and a recuperative food for cerebral fatigue, each including as active ingredients one or more members selected from the group consisting of chlorogenic acids, caffeic acid, ferulic acid, and pharmaceutically acceptable salts thereof. | 10-22-2009 |
20090306204 | Pharmaceutical Composition Comprising Cyclobenzaprine and Aceclofenac in Association - The present invention relates to an association of active ingredients. More specifically: to an association of cyclobenzaprine and aceclofenac. Additionally, the present invention is also related to the use of aceclofenac and cyclobenzaprine, in association for the preparation of a medicine useful in the treatment of painful muscular diseases, as well as to a method of treatment of painful muscular diseases using an association of aceclofenac and cyclobenzaprine. | 12-10-2009 |
20090318550 | Emulsions comprising at least one retinoid and benzoyl peroxide - Stable dermatological/cosmetic emulsions useful, e.g., for the treatment of acne vulgaris, contain, formulated into a physiologically acceptable medium, a homogeneous dispersion of at least one dispersed retinoid, dispersed benzoyl peroxide, at least one fatty phase, at least one hydrophilic phase and at least one emulsifier. | 12-24-2009 |
20090326066 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS - The invention relates to a process for producing a compound according to formula (i) | 12-31-2009 |
20100022642 | Dermatological/cosmetic compositions comprising a retinoid and benzoyl peroxide - Dermatological/cosmetic compositions contain, in a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and a gelling system comprising at least two categories of compounds. | 01-28-2010 |
20100029762 | Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris - A regimen for the safe and effective long-term treatment of acne vulgaris entails topically applying onto the affected skin area of a subject afflicted therewith, for a period of time of at least four (4) months, e.g., for at least twelve (12) months and advantageously on a daily basis and preferably once a day, a thus effective amount of a topical medicament containing adapalene and benzoyl peroxide, formulated into a pharmaceutically acceptable medium therefor. | 02-04-2010 |
20100069489 | L-THREONINE DERIVATIVES OF HIGH THERAPEUTIC INDEX - The present invention is directed to a derivative comprised of an L-Threonine bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. The derivative has the same utility as the drug from which it is made, but it has enhanced therapeutic properties. In fact, the derivatives of the present invention enhance at least one or more therapeutic qualities, as defined herein. The present invention is also directed to pharmaceutical compositions containing same. | 03-18-2010 |
20100087524 | Flavour Improving Substances - One aspect of the invention relates to a product selected from the group consisting of foodstuffs, beverages, oral care products, tobacco products and flavourings, said product containing at least 0.01 mg/kg of one or more flavour improving substances selected from the group of substituted phenol esters represented by the following the formula, salts of these compounds and combinations thereof: Formula (I). The invention also relates to novel substituted phenol esters represented by the above formula. Examples of the present flavour improving substances include lactoyl vanillin, lactoyl ethylvanillin, lactoyl isovanillin, lactoyl p-hydroxybenzaldehyde, lactoyl p-hydroxy-m-methoxycinnamaldehyde, lactoyl p-hydroxy-m-methoxycinnamic acid, lactoyl vanillic acid, lactoyl homovanillic acid, lactoyl-m-hydroxybenzoic acid, lactoyl isovanillic acid, lactoyl-p-hydroxy-m-methoxyacetophenone, oleyl vanillin, decanoyl vanillin, divanillyl succinate, lactoyl-o-hydroxy-m-methoxybenzaldehyde, lactoyl eugenol, gluconyl vanillin, and edible salts and esters thereof. | 04-08-2010 |
20100099761 | Levodopa Prodrug Mesylate Hydrate - Crystalline (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate, hydrate, methods of making the hydrate, pharmaceutical compositions containing the hydrate, and methods of using the hydrate to treat diseases or disorders such as Parkinson's disease are provided. | 04-22-2010 |
20100113592 | UNSYMMETRICAL AROMATIC ETHER DIACIDS AND ABSORBABLE POLYMERS THEREFROM - The present invention relates to compounds and compositions of formula I, which are unsymmetrical aromatic ether diacids, and polymers formed from the same. | 05-06-2010 |
20100130604 | USE OF ROSMARINIC ACID IN MANUFACTURE OF MEDICAMENTS FOR TREATING OR PREVENTING HEPATIC AND RENAL DISEASES - The present invention demonstrates through many experiments that Rosmarinic acid (RA) can inhibit the expression of connective tissue growth factor (CTGF) and therefore is useful for the prevention or treatment of hepatofibrosis and nephrofibrosis. Based on this, the present invention provides novel uses of RA and pharmaceutical compositions comprising the same in the manufacture of medicaments useful for the prevention or treatment of chronic hepatitis, CRF, and diabetic nephropathy. | 05-27-2010 |
20100144872 | New Methylenebisphenyl Compounds Useful in the Treatment of Inflammation - There is provided compounds of formula (I), wherein R | 06-10-2010 |
20100173990 | Transglutaminase Inhibitor Comprising Chlorogenic Acid And A Method For Producing Thereof - The present invention relates to a transglutaminase inhibitor comprising chlorogenic acid, a pharmaceutically acceptable salt thereof, or a derivative thereof. More particularly, the present invention relates to a transglutaminase inhibitor comprising chlorogenic acid, a pharmaceutically acceptable salt thereof, or a derivative thereof which effectively inhibits the activity of transglutaminase, the overexpression of which is responsible for the etiology of various diseases, and to novel uses thereof. The present invention provides a transglutaminase inhibitor and a method of inhibiting transglutaminase, both of which are based on using chlorogenic acid, a pharmaceutically acceptable salt thereof, or a derivative thereof as an active ingredient. Featuring the use of chlorogenic acid, a pharmaceutically acceptable salt thereof, or a derivative thereof, the novel method of inhibiting transglutaminase according to the present invention is safely applied to patients who suffer from the diseases caused by the overexpression of transglutaminase, thereby obtaining an inhibitory effect against transglutaminase without causing side-effects. | 07-08-2010 |
20100173991 | METHOD FOR THE SYNTHESIS OF A-RING AROMATIZED ACETYL MINOCYCLINES - The aim of the invention to provide a less complex method for the production of A-ring aromatized acetyl minocyclines of the formula (I), | 07-08-2010 |
20100173992 | LEVODOPA DIMETHYL-SUBSTITUTED DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE - Levodopa dimethyl-substituted diester prodrugs pharmaceutical, compositions comprising levodopa dimethyl-substituted diester prodrugs, and methods of using such prodrugs and pharmaceutical compositions for treating diseases such as Parkinson's disease are provided. | 07-08-2010 |
20100190854 | Composition and method to treat mastitis - A method is provided to produce a treatment composition which is sprayed externally on to the udder of a cow to treat mastitis. | 07-29-2010 |
20100216878 | Amino Acid Derivatives - The compound 3,3-dimethyl-butyric acid 4-((S)-2-amino-2-methoxycarbonyl-ethyl)-2-(3,3-dimethyl-butyryloxy)-phenyl ester of formula (I) has dopaminergic properties. | 08-26-2010 |
20100216879 | Resveratrol Ferulate Compounds And Compositions - Resveratrol ferulate compounds and compositions. | 08-26-2010 |
20100286267 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS - Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. The agent is a compound of Formula (I): wherein m is 0, 1, 2, 3, 4, 5, 6, 7 or 8; R | 11-11-2010 |
20100298430 | PROPHYLACTIC ANTISTRESS AGENT - The present invention relates to a prophylactic antistress agent and a central fatigue improver, which contain chlorogenic acids or pharmaceutically acceptable salts thereof as active ingredients. The present invention makes it possible to prevent and improve mental task fatigue, physical fatigue, central fatigue, central fatigue syndrome, overwork and the like. | 11-25-2010 |
20100298431 | Method of improving cognitive functions in individuals with down syndrome and/or alzheimer's disease - A method of treating an individual having Down syndrome or Alzheimer's disease, which entails the step of administering an amount of one or more compounds to the individual which improve cognitive functioning in the individual by increasing hippocampal NE levels. | 11-25-2010 |
20110034551 | METHODS OF INCREASING SARCOSINE LEVELS FOR TREATING SCHIZOPHRENIA - Methods for increasing sarcosine levels in a patient are provided. The methods include activating the PPARα receptor. Increasing sarcosine levels can be used, for example, as part of a treatment for schizophrenia. | 02-10-2011 |
20110054022 | Method for Preparing Dicaffeoylquinic Acids and Use Thereof in Combating Aphids - Method for preparing 3,5-dicaffeoylquinic acid and certain derivatives thereof, and use thereof in the preparation of plant-protection products. Method for combating aphids using 3,5-dicaffeoylquinic acid and certain derivatives thereof. | 03-03-2011 |
20110086912 | Derivatives of Propane Diyl Dicinnamate - The present invention provides a method for treating a cancer in a subject involving administering to the subject a compound of formula (II) or (II′): | 04-14-2011 |
20110092591 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS - The present invention is related to a family of phenyl-prenyl derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the compounds of formula (I) for medical use, particularly for the use for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder, and to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder. | 04-21-2011 |
20110105606 | Compositions and methods affecting the signaling pathways of LRP receptors - The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands. | 05-05-2011 |
20110105607 | LIPOPHILIC DIESTERS OF CHELATING AGENT FOR INHIBITION OF ENZYME ACTIVITY - The present invention relates to the use of lipophilic diesters of the chelating agent 1,2-bis(2 aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA) for inhibition of proteolytic activities of certain metalloproteinases, calpain and TACE | 05-05-2011 |
20110178173 | Anti-degradation agent - There is provided an anti-degradation agent capable of exhibiting an excellent deterioration-inhibiting property for foods, cosmetics, etc., showing a good effect even when added in a small amount, having a high heat resistance, and being free from adverse influence due to light. There are provided (1) an anti-degradation agent comprising a water-insoluble antioxidant, a water-soluble antioxidant and an emulsifying agent; and (2) an anti-degradation agent comprising a water-soluble antioxidant, and carnosol and/or carnosic acid wherein a total content of the carnosol and the carnosic acid is not less than 4% by weight. | 07-21-2011 |
20110207816 | ALTERNATE MORPHEEINS OF ALLOSTERIC PROTEINS AS A TARGET FOR THE DEVELOPMENT OF BIOACTIVE MOLECULES - A composition having an agent adapted to affect a multimeric protein by binding to a binding site of the multimeric protein and thereby affecting an equilibrium of units, wherein the multimeric protein has an assembly having a plurality of said units, wherein each of the units has a first complementary surface and a second complementary surface and wherein the first complementary surface of one unit is associated with the second complementary surface of another unit, provided that the assembly is at least one of different quaternary isoforms on a condition that in the multimeric protein (1) a structure of each of the units determines a structure of the different quaternary isoforms, (2) the units are in the equilibrium and (3) the structure of the different quaternary isoforms influences a function of the multimeric protein. | 08-25-2011 |
20110245336 | COLCHICINE SOLID COMPLEX; METHODS OF MAKING; AND METHODS OF USE THEREOF - Disclosed are new colchicine solid complexes, methods of making the solid complexes as well as formulations prepared therefrom and uses thereof. | 10-06-2011 |
20110301235 | ORGANOSELENIUM COMPOUNDS AND USES THEREOF - Provided herein are organoselenium compounds and pharmaceutical compositions thereof. Also provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders using the compounds and pharmaceutical compositions provided herein. | 12-08-2011 |
20120010285 | AGENT FOR PROMOTING ENERGY CONSUMPTION - Provision of a pharmaceutical product, a quasi-drug, a food, a beverage, a pet food, a feed, and others which are highly safe, have excellent action of promoting energy consumption, promoting fat burning, promoting carbohydrate burning, or improving an effect of exercise, and which are effective for the prevention or amelioration of obesity or metabolic syndrome or the improvement of motor functions. | 01-12-2012 |
20120022157 | DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS - The invention provides a method for determining a dose and dosing schedule, and making dose adjustments of patients taking PBA prodrugs as nitrogen scavengers to treat nitrogen retention states, including ammonia accumulation disorders as well as chronic renal failure, by measuring urinary excretion of phenylacetylglutamine and/or total urinary nitrogen. The invention provides methods to select an appropriate dosage of a PBA prodrug based on the patient's dietary protein intake, or based on previous treatments administered to the patient. The methods are applicable to selecting or modifying a dosing regimen for a subject receiving an orally administered waste nitrogen scavenging drug, and to monitoring patients receiving such drugs. | 01-26-2012 |
20120041062 | COMPOUND OF SALVIANOLIC ACID L, PREPARATION METHOD AND USE THEREOF - The present invention relates to a new compound of salvianolic acid L, its preparation method, a pharmaceutical composition containing the salvianolic acid L, and its use for preparing a medicament for treating cardio-cerebrovascular diseases. | 02-16-2012 |
20120115947 | COMBINATION/ASSOCIATION OF ADAPALENE AND BENZOYL PEROXIDE FOR TREATING ACNE LESIONS - Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO). | 05-10-2012 |
20120122977 | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors - The present invention provides a compound of formula I; | 05-17-2012 |
20120184616 | Methods for treating inflammation - The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands. | 07-19-2012 |
20120196929 | Use of Rosmarinic Acid and the Derivaties Thereof to Treat Ciguatera - The present invention relates to rosmarinic acid and to the derivatives thereof, expressed by the compounds of general formula (I), for the use thereof to prevent and/or treat disorders caused by ciguatoxin poisoning and for preparing a pharmaceutical composition for preventing and/or treating disorders caused by ciguatoxin poisoning. | 08-02-2012 |
20120208882 | Organic Compounds - The invention describes novel pharmaceutically acceptable salt forms of camostat, processes for lyophilisation, taste-masked formulations, nebulised formulations and the use of each of the fore-going in the treatment of respiratory diseases, particularly cystic fibrosis and chronic obstructive pulmonary disease (COPD). | 08-16-2012 |
20120277308 | COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES - This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins. It inhibits excess adhesion and inhibits cell attachment. It modulates angiogenesis. The compounds also use as mediator of cell adhesion receptor, cell circulating, cell moving and inflammatory diseases. | 11-01-2012 |
20120283325 | EXCIPIENT COMPATIBILITY WITH EZATIOSTAT - Disclosed herein is the surprising and unexpected discovery that mannitol inhibits the growth of impurities and enhances shelf life of ezatiostat hydrochloride formulations. | 11-08-2012 |
20120302636 | METHOD OF TREATING A DISORDER ASSOCIATED WITH MTP - Provided is a method of treating or preventing a disorder in a subject comprising administering twice per day a therapeutically effective amount of a compound of formula (I) | 11-29-2012 |
20120329871 | ANTIMICROBIAL COMPOUNDS - A compound for use as an antimicrobial having a formula (A). | 12-27-2012 |
20130035388 | Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex - This patent pertains to selective inhibition of assembly of the membrane attack complex of complement by use of less than 1 kDa molecular weight forms of the aurin tricarboxylic acid synthetic complex (ATAC), and their derivatives. It further pertains to the use of these materials to treat human conditions where there is evidence of self destruction of host tissue by the membrane attack complex. These diseases include, but are not limited to, Alzheimer disease, age related macular degeneration, and atherosclerosis. | 02-07-2013 |
20130035389 | METHODS FOR TREATING MYELODYSPLASTIC SYNDROME WITH EZATIOSTAT - This invention relates to methods, assays, devices and systems for identifying patients having a myelodysplastic syndrome for treatment with ezatiostat or a salt thereof, or evaluating the patient's response possibility to the treatment by measuring and evaluating the patient's gene expression profile. This invention also relates to methods of treating myelodysplastic syndromes. | 02-07-2013 |
20130085179 | METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS - The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders. | 04-04-2013 |
20130131165 | PROCESS FOR PRODUCTION OF PURIFIED CHLOROGENIC ACID-CONTAINING PHARMACEUTICAL PREPARATION - Provided is a process for producing a purified chlorogenic acid-containing preparation, which is useful for the production of a chlorogenic acid-containing beverage with reduced developability of turbidity even in an acidic range. | 05-23-2013 |
20130184344 | LEVODOPA PRODRUG MESYLATE HYDRATE - Crystalline (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate, hydrate, methods of making the hydrate, pharmaceutical compositions containing the hydrate, and methods of using the hydrate to treat diseases or disorders such as Parkinson's disease are provided. | 07-18-2013 |
20130203847 | Pharmaceutical Formulation for Histone Deacetylase Inhibitors - A pharmaceutical composition, comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound represented by the following structural formula at least one acidifying agent; and a vehicle base comprising at least one pharmaceutically acceptable non-aqueous solvent. Values and preferred values of the variables in structural formula (I) are defined herein. | 08-08-2013 |
20130210913 | ANTI-TUMOR AND ANTI-INFLAMMATORY DICINNAMOYL-GLYCEROL ESTERS AND THEIR ANALOGUES - Synthetic dicinnamate compounds and their analogues are disclosed that exhibit anti-tumor activity and/or an anti-inflammatory activity, and have beneficial activity principally in destroying cancer cells. Furthermore, methods for the extraction of the extracts are disclosed. | 08-15-2013 |
20130210914 | METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS - The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders. | 08-15-2013 |
20130217768 | SIMPLE PROCESS TO PRODUCE AND SEPARATE WATER SOLUBLE AND OIL SOLUBLE ANTIOXIDATIVE FLAVORING COMPOSITIONS FROM LABIATAE HERBS USING GREEN SOLVENTS - Processes for preparing water soluble and oil soluble antioxidant compositions extracted together from Labiatae herbs in a single extraction using an alcohol and water solvent, followed by a simple, yet effective purification step that allows the separation of the water soluble antioxidative fractions containing mainly rosmarinic acid from antioxidative fractions containing mainly carnosic acid and carnosol, without cumbersome acid/base partitioning steps. | 08-22-2013 |
20130225681 | Phenylketone Carboxylate Compounds and Pharmaceutical Uses Thereof - Phenylketone carboxylate compounds of Formula I, wherein n=2-6; R═C(0); —OC(O)— or —CH(OH)—; A is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when B is Ft B is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when A is Ft or A and B form a 5-7 membered cycloalkyl substituted with COOFt W=0, S or NFt Y=0,S,NH or CH2; m=0-2; p=1-7; have been prepared. These compounds and their pharmaceutically acceptable salts have beneficial therapeutic effects to prevent or treat a condition related to (l) blood disorders, (ii) inflammation related diseases, (iii) renal disorders and/or renal disorders complications, or (iv) fibrosis-related organ dysfunction. | 08-29-2013 |
20130231388 | (CARBOXYLALKYLENEPHENYL)PHENYLOXAMIDES, METHOD FOR THE PRODUCTION THEREOF AND USE OF SAME AS A MEDICAMENT - The invention relates to (carboxylalkylenephenyl)phenyloxamides and their physiologically tolerated salts, and their use as a medicament. | 09-05-2013 |
20130281530 | METHODS OF THERAPEUTIC MONITORING OF PHENYLACETIC ACID PRODRUGS - The present disclosure provides methods for adjusting the dosage of PAA prodrugs (e.g., HPN-100, PBA) based on measurement of PAA and PAGN in plasma and calculating the PAA:PAGN ratio so as to determine whether PAA to PAGN conversion is saturated. | 10-24-2013 |
20130303611 | USE OF PHENETHYL CAFFEATE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT AGAINST TUMOR ANGIOGENESIS - Disclosed is the use of the compounds represented by formula (I) in the preparation of a medicament against tumor angiogenesis, wherein R | 11-14-2013 |
20130310454 | PHARMACEUTICAL COMPOSITION COMPRISING EXTRACT OF LONICERA JAPONICA FOR PREVENTION AND TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE - Disclosed is a composition for treating or preventing gastroesophageal reflux disease, which includes an organic solvent extract of Lonicerae Flos Thunberg. A fraction of the disclosed extract can be very effectively used for treating, preventing, or improving gastroesophageal reflux disease without side effects. | 11-21-2013 |
20130317102 | Novel Esters of (Acyloxymethyl)Acrylamide, a Pharmaceutical Composition Containing Them, and Their use as Inhibitors of the Thioredoxin - Thioredoxin Reductase System - The subject of the present invention are novel esters of (acyloxymethyl)acrylamide, a pharmaceutical composition containing them and their use in the production of drugs for the prophylaxis or treatment of oncogenic diseases and diseases connected with increased cell proliferation. | 11-28-2013 |
20140011873 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF STROKE - Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects. | 01-09-2014 |
20140045937 | METHODS OF TREATING POLYCYSTIC OVARIAN SYNDROME USING CHLOROGENIC ACID - The invention provides a method of treating or preventing polycystic ovarian syndrome (PCOS) in a mammal, comprising administering chlorogenic acid in an amount effective to treat or prevent PCOS in the mammal. In an embodiment of the invention, the method further comprises administering L-cysteine to the mammal. | 02-13-2014 |
20140113964 | METHOD OF PREVENTING AND TREATING ALLERGIC AIRWAY DISEASES VIA INTRANASAL GABEXATE MESILATE - The present invention discloses a method of preventing and treating allergic airway diseases via intranasal gabexate mesilate, comprising administrating a pharmaceutically effective amount of a composition comprising a gabexate mesilate via nasal spray to prevent and treat allergy induced by a serine protease type allergen. | 04-24-2014 |
20140135391 | METHOD FOR MANUFACTURING REFINED CHLOROGENIC ACIDS COMPOSITION - Provided is a method for producing a chlorogenic acids composition having a reduced caffeine content and good taste and favor, capable of efficiently recovering high purity of chlorogenic acids from a chlorogenic acids-containing composition. The method for producing a purified chlorogenic acids composition comprises a step A of bringing a chlorogenic acids-containing composition into contact with a cation exchange resin; a step B of bringing the liquid obtained in the step A into contact with an anion exchange resin; and a step C of bringing an eluent into contact with the anion exchange resin after the step B. | 05-15-2014 |
20140187630 | NOVEL COMPOUND AND MEDICAL USE THEREOF - Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2S)-2-Amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid, a salt thereof, or a solvate thereof is a levodopa prodrug, and provides a flat blood concentration-time profile of levodopa through oral administration, and therefore is useful as a preventive and/or therapeutic agent for Parkinson's disease and/or Parkinson's syndrome that overcomes the problems associated with pharmaceutical preparations of levodopa. | 07-03-2014 |
20140206763 | PHENYLBUTYRATE FOR TREATMENT OF SPORADIC INCLUSION-BODY MYOSITIS AND DISORDERS RELATING TO AUTOPHAGY IMPAIRMENT OR AMYLOID BETA 42 ACCUMULATION - Disclosed is a method of improving lysosomal activity in a patient in need thereof including administering to the patient an effective amount of phenylbutyrate, preferably 4-phenylbutyrate in the form of at least one of sodium phenylbutyrate or glycerol phenylbutyrate. Also disclosed a method of improving lysosomal activity or ameliorating a pathological phenotype in a cell having impaired autophagy comprising treating the cell with phenylbutyrate, preferably 4-phenylbutyrate in the form of at least one of NaBP or GPB. The phenylbutyrate is generally administered in the form of a pharmaceutical composition including the phenylbutyrate and at least one carrier. | 07-24-2014 |
20140256807 | METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS - The invention provides a method for determining a dose and schedule and making dose adjustments of PBA prodrugs used to treat nitrogen retention states, or ammonia accumulation disorders, by measuring urinary excretion of phenylacetylglutamine and/or total urinary nitrogen. The invention provides methods to select an appropriate dosage of a PBA prodrug based on the patient's dietary protein intake, or based on previous treatments administered to the patient. The methods are applicable to selecting or modifying a dosing regimen for a subject receiving an orally administered ammonia scavenging drug. | 09-11-2014 |
20140303247 | MEMBRANE ACTIVATED CHELATORS AND USE IN THE PREVENTION AND TREATMENT OF PARASITIC INFECTION - Provided herein are pharmaceutical compositions useful in the prevention and treatment of protozoan infections in mammals comprising administering to the subject a pharmaceutical composition comprising at least one membrane activated chelator compound which is a lipophilic diester derivative of the chelating agent 1,2-bis(2 aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid, or a salt, solvate, stereoisomer, or prodrug thereof, as well as compositions which include at least one or more other anti-parasitic compound, and a pharmaceutically acceptable carrier, in an effective amount. Methods for prevention, treatment, and combination therapies are also provided. | 10-09-2014 |
20140371310 | MANDELIC ACID CONDENSATION POLYMERS - Disclosed herein are compounds and compositions useful for reducing the risk of infection. In particular, disclosed herein are mandelic acid condensation polymers, compositions comprising such compounds, processes for producing such compounds, and methods of using such compounds. | 12-18-2014 |
20140378541 | Synthetic Epigallocatechin Gallate (EGCG) Analogs - Synthetic polyphenolic compounds of formula (I), their modes of synthesis, and pharmaceutical compositions thereof are provided herein. Use of the compounds and compositions described herein for treating cancer and for treating metabolic disorders is also provided. | 12-25-2014 |
20150011629 | BIOACTIVE DEPSIDE AND ANTHOCYANIN COMPOUNDS, COMPOSITIONS, AND METHODS OF USE - Methods for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside or an anthocyanin are provided. More particularly, a method for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside having the structure of formula (IV): Formula (IV) wherein R is selected from H or CH | 01-08-2015 |
20150038581 | HISTONE DEACETYLASE INHIBITORS - In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for example. The present invention also provides methods for preparing compounds of the invention and intermediates thereto. | 02-05-2015 |
20150065570 | AGENT FOR INDUCING THE SYNTHESIS OF HEAT-SHOCK PROTEINS IN HUMAN AND ANIMAL CELLS - An agent induces heat shock protein in human and animal cells. The agent includes at least one phenol compound that is a cinnamic acid derivative and at least one nonionic surfactant. The agent is useful in cosmetic preparations, food supplements and foodstuffs. | 03-05-2015 |
20150087703 | COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISEASE - The present invention provides a method and composition for treating a neurodegenerative disease. In particular, the present invention provides a method and composition to increase DJ-1 gene expression or DJ-1 protein activity to treat a neurodegenerative disease. | 03-26-2015 |
20150328179 | DICAFFEOYLQUINIC ACID-CONTAINING DRINK - A dicaffeoylquinic acid-containing beverage of the present invention includes the following components (A) and (B): (A) 0.02 to 0.18 mass % of dicaffeoylquinic acids; and (B) 0.1 to 1.0 mass % of L-arginine, in which a mass ratio between the component (A) and the component (B), [(B)/(A)], is from 2 to 18. | 11-19-2015 |
20150335605 | METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS - The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders. | 11-26-2015 |
20160074319 | TOPICAL COMPOSITION CONTAINING ANTIOXIDANTS - Disclosed herein are compositions for topical application that effectively deliver antioxidants across the epidermis, dermis, or a combination thereof into cells and/or the bloodstream while concurrently maintaining chemical activity of the antioxidants. In certain aspects, these formulations include emulsions and balms each having a lipophilic carrier and a lipophilic antioxidant solubilized by the lipophilic carrier. Also disclosed herein are methods for making these compositions for topical application. | 03-17-2016 |
20160074356 | METHODS OF TREATING UREA CYCLE DISORDERS - The present disclosure provides novel methods for determining an effective dosage of a PAA prodrug and for treating a UCD that incorporate body surface area and urinary PAGN concentration. The disclosure further provides novel methods for assessing compliance with PAA prodrug administration that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, or age. The disclosure further provides novel methods of treating a UCD in a subject in need thereof that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, and/or age. | 03-17-2016 |
20160081967 | COMPOSITIONS OF CHLOROGENIC ACID AND METHODS FOR MAKING AND USING THE SAME IN OBESITY MANAGEMENT - The present invention is directed compositions derived from green coffee bean extract and methods for the use and manufacture of such compositions. The compositions of the invention have unique ratios of chlorogenic acids which offer a therapeutic effect in the treatment of a variety of conditions and disorders. Methods for using the compositions of the invention include, but not limited to, methods for treating obesity and methods for regulating serum lipids. | 03-24-2016 |
20160081969 | METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS - The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders. | 03-24-2016 |
20160106700 | Pharmaceutical Formulation for Histone Deacetylase Inhibitors - A pharmaceutical composition, comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound represented by the following structural formula | 04-21-2016 |
20160166522 | TREATMENT OF MEDIUM-CHAIN ACYL-CoA DEHYDROGENASE DEFICIENCY | 06-16-2016 |
20160199332 | METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS | 07-14-2016 |
20160199333 | METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS | 07-14-2016 |
20160199334 | METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS | 07-14-2016 |
20160200661 | NEW SALVIANOLIC ACID COMPOUND T, PREPARATION METHOD THEREFOR, AND USE THEREOF | 07-14-2016 |
20160202240 | METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS | 07-14-2016 |
20180021291 | METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS | 01-25-2018 |
20180021292 | METHODS OF TREATING UREA CYCLE DISORDERS | 01-25-2018 |
20180021293 | METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS | 01-25-2018 |